Legislative and Regulatory Responses to the FTC Study on Barriers to Entry in the Pharmaceutical Marketplace: Hearing Before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, First Session, June 17, 2003
U.S. Government Printing Office, 2003 - Competition - 116 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
30-month stay abuse action additional Administration affordable agreements allow Amendments American ANDA applicant approval believe bill billion brand brand name brand-name company bring Chairman HATCH challenge changes claim Commission Committee competition concerns Congress constitutional consumers continue controversy costs court court decision delay discuss district drug companies drug manufacturers drug product effective ensure enter entry exclusivity FDA approval FDA’s Federal Federal Trade Commission ﬁled ﬁling ﬁrst FTC Study going Hatch-Waxman hearing holder improper incentive increase innovator invalid involved issue lawsuit legislation limit litigation medicines months Orange Book paragraph IV certiﬁcation passed patent infringement patent listing percent period pharmaceutical potential prescription drugs prior proposed protection provision question recommendations regulations rule savings Senator settlements submitted suit Thank trigger